Active, not recruitingPhase 4NCT05300932

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
AIHUA DU
Tongji Hospital
Intervention
Baricitinib(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2026

Study locations (2)

Collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Renmin Hospital of Wuhan University · Eli Lilly and Company · Johns Hopkins University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05300932 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials